Unique biochemical, cytotoxic, and antitumor activity of camptothecin and 4beta-amino-4'-O-demethylepipodophyllotoxin conjugates.

[1]  W. Sause.  The role of radiotherapy in non-small cell lung cancer. , 1999, Chest.

[2]  Y. Cheng,et al.  Decreased drug accumulation without increased drug efflux in a novel MRP-overexpressing multidrug-resistant cell line. , 1998, Biochemical pharmacology.

[3]  M. Stahl,et al.  Down-regulation of topoisomerase II by camptothecin does not prevent additive activity of the topoisomerase II inhibitor etoposide in vitro , 1997, Anti-cancer drugs.

[4]  Y. Cheng,et al.  Antitumor agents--CLXXIII. Synthesis and evaluation of camptothecin-4 beta-amino-4'-O-demethyl epipodophyllotoxin conjugates as inhibitors of mammalian DNA topoisomerases and as cytotoxic agents. , 1997, Bioorganic & medicinal chemistry.

[5]  K. Lee,et al.  Recent advances in the discovery and development of topoisomerase inhibitors as antitumor agents , 1997, Medicinal research reviews.

[6]  R. Ganapathi,et al.  Cytotoxic Efficacy with Combinations of Topoisomerase I and Topoisomerase II Inhibitors in Sensitive and Multidrugresistant L1210 Mouse Leukemia Cells a , 1996, Annals of the New York Academy of Sciences.

[7]  S. Sawada,et al.  Synthesis of CPT‐11 (Irinotecan Hydrochloride Trihydrate) , 1996, Annals of the New York Academy of Sciences.

[8]  T. Tsuruo,et al.  Antitumor activity of a novel podophyllotoxin derivative (TOP-53) against lung cancer and lung metastatic cancer. , 1996, Cancer research.

[9]  Y. Cheng,et al.  Activities of novel nonglycosidic epipodophyllotoxins in etoposide-sensitive and -resistant variants of human KB cells, P-388 cells, and in vivo multidrug-resistant murine leukemia cells. , 1996, Molecular pharmacology.

[10]  Y. Cheng,et al.  Camptothecin resistance involving steps subsequent to the formation of protein-linked DNA breaks in human camptothecin-resistant KB cell lines. , 1996, Cancer research.

[11]  Y. Pommier,et al.  Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen. , 1995, Cancer research.

[12]  S. Chatterjee,et al.  Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens. , 1994, Oncology research.

[13]  L. Liu,et al.  Interaction between replication forks and topoisomerase I-DNA cleavable complexes: studies in a cell-free SV40 DNA replication system. , 1993, Cancer research.

[14]  Y. Pommier,et al.  Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials. , 1993, Molecular pharmacology.

[15]  T Takahashi,et al.  Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. , 1993, Cancer research.

[16]  S. Bouffler,et al.  Cockayne's syndrome fibroblasts are characterized by hypersensitivity to deoxyguanosine and abnormal DNA precursor pool metabolism in response to deoxyguanosine or ultraviolet light , 1992, Somatic cell and molecular genetics.

[17]  Y. Cheng,et al.  Characterization of camptothecin-resistant Chinese hamster lung cells. , 1992, Biochemical pharmacology.

[18]  Y. Pommier,et al.  Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells. , 1992, European journal of cancer.

[19]  Y. Pommier,et al.  Topoisomerase I alteration in a camptothecin-resistant cell line derived from Chinese hamster DC3F cells in culture. , 1992, Cancer research.

[20]  L. Liu,et al.  The involvement of active DNA synthesis in camptothecin-induced G2 arrest: altered regulation of p34cdc2/cyclin B. , 1992, Cancer research.

[21]  H. Nakano,et al.  Induction of mammalian DNA topoisomerase I and II mediated DNA cleavage by saintopin, a new antitumor agent from fungus. , 1991, Biochemistry.

[22]  Y. Cheng,et al.  Effect of 4 beta-arylamino derivatives of 4'-O-demethylepipodophyllotoxin on human DNA topoisomerase II, tubulin polymerization, KB cells, and their resistant variants. , 1991, Cancer research.

[23]  S. Kaufmann,et al.  Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. , 1991, Cancer research.

[24]  T. Tsuruo,et al.  Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines. , 1990, Cancer research.

[25]  R. Hertzberg,et al.  Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content. , 1990, Molecular pharmacology.

[26]  K. Kohn,et al.  Sequence-selective topoisomerase II inhibition by anthracycline derivatives in SV40 DNA: relationship with DNA binding affinity and cytotoxicity. , 1990, Biochemistry.

[27]  T. Andoh,et al.  Collateral drug sensitivity induced in CPT-11 (a novel derivative of camptothecin)-resistant cell lines. , 1990, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[28]  L. Liu,et al.  DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts. , 1989, Science.

[29]  Y. Pommier,et al.  Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. , 1989, Cancer research.

[30]  L. Liu,et al.  Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. , 1989, Cancer research.

[31]  Y. Cheng,et al.  Podophyllotoxin analogs: effects on DNA topoisomerase II, tubulin polymerization, human tumor KB cells, and their VP-16-resistant variants. , 1989, Molecular pharmacology.

[32]  Y. Cheng,et al.  Combined modalities of resistance in etoposide-resistant human KB cell lines. , 1988, Cancer research.

[33]  A. Montecucco,et al.  DNA unwinding and inhibition of T4 DNA ligase by anthracyclines. , 1988, Nucleic acids research.

[34]  L. Liu,et al.  Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. , 1988, Cancer research.

[35]  Y. Suzuki,et al.  Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[36]  J. Wang.  Recent studies of DNA topoisomerases. , 1987, Biochimica et biophysica acta.

[37]  F. Della Seta,et al.  Structure of RNA polymerase II promoters. Conformational alterations and template properties of circularized Saccharomyces cerevisiae GAL1‐GAL10 divergent promoters. , 1986, The EMBO journal.

[38]  L. Liu,et al.  DNA damage by antitumor acridines mediated by mammalian DNA topoisomerase II. , 1986, Cancer research.

[39]  R. Hertzberg,et al.  Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. , 1985, The Journal of biological chemistry.

[40]  B. Fox.  Etoposide (VP-16): Current Status and New Developments , 1985 .

[41]  L. Liu,et al.  Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage. , 1984, Cancer research.

[42]  L. Liu,et al.  Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. , 1984, The Journal of biological chemistry.

[43]  L. Liu,et al.  Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. , 1984, Science.

[44]  W. Wilson,et al.  A semiautomated microculture method for investigating growth inhibitory effects of cytotoxic compounds on exponentially growing carcinoma cells. , 1984, Analytical biochemistry.

[45]  L. Liu,et al.  Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. , 1984, The Journal of biological chemistry.

[46]  L. Liu,et al.  Novel topologically knotted DNA from bacteriophage P4 capsids: studies with DNA topoisomerases. , 1981, Nucleic acids research.

[47]  L. Liu,et al.  Eukaryotic DNA topoisomerases: two forms of type I DNA topoisomerases from HeLa cell nuclei. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[48]  W. Denny,et al.  Potential antitumor agents. 35. Quantitative relationships between antitumor (L1210) potency and DNA binding for 4'-(9-acridinylamino)methanesulfon-m-anisidide analogues. , 1981, Journal of medicinal chemistry.

[49]  B. C. Baguley,et al.  The interaction of ethidium with synthetic double-stranded polynucleotides at low ionic strength , 1978, Nucleic Acids Res..

[50]  J. Jett,et al.  Mathematical analysis of DNA histograms from asynchronous and synchronous cell populations , 1977 .

[51]  J. Double,et al.  Transplantable colon tumors as chemotherapy screening models , 1975, Cancer.

[52]  M. Horwitz,et al.  Effects of camptothecin on the breakage and repair of DNA during the cell cycle. , 1973, Cancer research.

[53]  L. Li,et al.  Action of camptothecin on mammalian cells in culture. , 1972, Cancer research.

[54]  R. Adamson,et al.  Studies on the antitumor activity, mechanism of action, and cell cycle effects of camptothecin. , 1971, Journal of the National Cancer Institute.